- POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds of $125 million.
- The offer price represents a discount of almost 12% from the last close price of $10.18 on Tuesday.
- Underwriters have an option to purchase up to an additional 2.01 million shares.
- POINT will use the proceeds to fund clinical and preclinical research and development programs.
- Related: POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate.
- Akero Therapeutics Inc (NASDAQ:AKRO) commenced an underwritten public offering of $175.0 million.
- Underwriters have an option to purchase up to an additional $26.25 million of shares.
- Related: Akero Therapeutics Shares More Than Double After Lead NASH Candidate Aces Mid-Stage Study
- Price Action: AKRO shares are down 6.51% at $27.16, and PNT shares are down 11.40% at $9.02 on the last check Wednesday.
Dow Rises 50 Points; Quoin Pharmaceuticals Shares Plunge
U.S. stocks traded slightly higher toward the end of trading following the release of Fed minutes.
The Dow traded up 0.15% to 33,180.87 while the NASDAQ rose 0.49% to 11,548.73. The S&P 500 also rose, gaining, 0.33% to 4,010.53.
